{"title": "Nucleotide Analogues as Inhibitors of Viral Polymerases", "doi": "10.1101/2020.01.30.927574", "citation_id": "2020.01.30.927574v1", "date": "2020-01-31", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.01.30.927574", "abstract": "<h3>Summary</h3>\n<p>Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3\u2019-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.</p>", "twitter_description": "Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3\u2019-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.30.927574.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.01.30.927574v1", "access_rights": "restricted", "authors": ["Jingyue Ju", "Shiv Kumar", "Xiaoxu Li", "Steffen Jockusch", "James J. Russo"]}